Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $97.2857.

A number of analysts have issued reports on the company. Citizens Jmp boosted their target price on Lantheus from $85.00 to $115.00 and gave the company a “market outperform” rating in a research report on Friday. William Blair restated an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. B. Riley Financial restated a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Finally, Wall Street Zen downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday.

Lantheus Stock Up 2.3%

Shares of NASDAQ LNTH opened at $93.06 on Monday. The firm has a market cap of $6.06 billion, a price-to-earnings ratio of 22.42 and a beta of -0.08. The company has a quick ratio of 2.51, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. Lantheus has a 52-week low of $47.25 and a 52-week high of $94.86. The business’s 50 day moving average is $79.69 and its two-hundred day moving average is $68.87.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. The company had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts predict that Lantheus will post 4.26 EPS for the current year.

Hedge Funds Weigh In On Lantheus

Institutional investors and hedge funds have recently modified their holdings of the company. Osterweis Capital Management Inc. purchased a new stake in Lantheus in the second quarter valued at $36,000. Hantz Financial Services Inc. raised its holdings in shares of Lantheus by 412.5% in the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 396 shares during the last quarter. First Horizon Corp purchased a new position in Lantheus during the third quarter worth about $26,000. Smartleaf Asset Management LLC raised its holdings in Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares in the last quarter. Finally, Bessemer Group Inc. raised its holdings in Lantheus by 221.3% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 354 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus News Summary

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Lantheus reported first-quarter EPS of $1.46, beating estimates of $1.25, on revenue of $377.3 million, also above expectations. The beat suggests solid underlying demand and execution. Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: The company issued FY2026 EPS guidance of $5.00 to $5.25, slightly above the consensus estimate, reinforcing expectations for continued profitability. Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Citizens JMP raised its price target to $115 from $85 and reiterated a Market Outperform rating, implying meaningful upside from current levels. Tickerreport.com
• Positive Sentiment: Mizuho also lifted its price target to $100 from $95 and kept an Outperform rating, adding to the bullish post-earnings analyst momentum. Benzinga
• Neutral Sentiment: Several follow-up stories highlighted valuation and the earnings call transcript, but these were mainly commentary on the already-reported results rather than new catalysts. Lantheus Holdings (LNTH) Valuation Check After Q1 Earnings Beat And FDA Approval Catalysts

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.